Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term carcinomas. Found 33 abstracts

no pagination
De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clinical Breast Cancer. 2012 Aug;12(4):264-9.   PMCID: not NIH funded
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics. 2012 Nov;11(11):2526-34.   PMCID: PMC 3500676
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2012 Jul;134(2):751-7.
Tchou J, Wang LC, Selven B, Zhang HT, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Research and Treatment. 2012 Jun;133(2):799-804.
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the Antiapoptotic Protein Survivin in Colon Cancer. Clinical Colorectal Cancer. 2011 Sep;10(3):188-93.   PMCID: not NIH funded
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus. Cancer. 2011 Apr;117(7):1409-14.   PMCID: PMC3116987
Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA. Advanced Stage Mucinous Adenocarcinoma of the Ovary Is Both Rare and Highly Lethal A Gynecologic Oncology Group Study. Cancer. 2011 Feb;117(3):554-62.   PMCID: PMC3010456
Betancourt AM, Eltoum IA, Desmond RA, Russo J, Lamartiniere CA. In Utero Exposure to Bisphenol A Shifts the Window of Susceptibility for Mammary Carcinogenesis in the Rat. Environmental Health Perspectives. 2010 Nov;118(11):1614-9.   PMCID: PMCID: PMC2974702
Dong XY, Guo P, Boyd J, Sun XD, Li QN, Zhou W, Dong JT. Implication of snoRNA U50 in human breast cancer. Journal of Genetics and Genomics. 2009 Aug;36(8):447-54.   PMCID: PMCID: PMC2854654
Caslini C, D Capo-Chichi C, Roland IH, Nicolas E, T Yeung A, Xu XX. Histone modifications silence the GATA transcription factor genes in ovarian cancer. ONCOGENE. 2006 Aug;25(39):5446-61.
Morrow M. Magnetic resonance imaging in breast cancer: Is seeing always believing?. European Journal of Cancer. 2005 Jul;41(10):1368-9.
Russo J, Russo IH. Genotoxicity of steroidal estrogens. Trends in Endocrinology and Metabolism. 2004 Jul;15(5):211-4.
Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000 Feb 21;19(8):968-88.
Balsara BR, Bell DW, Sonoda G, De Rienzo A, du Manoir S, Jhanwar SC, Testa JR. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Research. 1999 Jan 15;59(2):450-4.
Hamilton TC, Berek JS, Kaye SB. Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?. Annals of Oncology. 1999 Jan;10:69-73.
Zekri AR, Bahnassi AA, Bove B, Huang YJ, Russo IH, Rogatko A, Shaarawy S, Shawki OA, Hamza MR, Omer S, Khaled HM, Russo J. Allelic instability as a predictor of survival in Egyptian breast cancer patients. International Journal of Oncology. 1999 Oct;15(4):757-67.
Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Benedetti-Panici P, Mancuso S. Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression. International journal of cancer. 1998 Jan 05;75(1):34-9.
Mitsuuchi Y, Johnson SW, Moonblatt S, Testa JR. Translocation and activation of AKT2 in response to stimulation by insulin. Journal of cellular biochemistry. 1998 Sep 15;70(4):433-41.
Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King MC, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, Offit K. The APC I1307K allele and breast cancer risk. Nature genetics. 1998 Sep;20(1):13-4.
Ruggeri BA, Huang LY, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molecular Carcinogenesis. 1998 Feb;21(2):81-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term carcinomas

carcinomas expression heterozygosity tumor-suppressor gene cancer frequent loss tumors inhibition microsatellite instability inhibitor mutations breast-cancer 6q breast cancer oncogene lymphopenia cell proliferation bisphenol A-endocrine disruptors-mammary cancer-susceptibility signaling proteins ovarian epithelial cells rad51 bcl-2 family-members snoRNA protein-kinase assay activation marrow rna regions targeting survivin receptor tamoxifen overrepresentation gene-expression nf2 genes progression molecular- candidate Cell Biology combination Prognostic factors CT growth risk pancreatic cancer growth-factor-alpha receptors disposition chromosome 13q12-q13 prognosis transgenic mice breast tumor sites Survivin phosphatidylinositol 3-kinase Circulating tumor cells Bone metastases-Lymphocytopenia-Metastatic breast cancer-PET krukenberg tumor Biochemistry & Molecular Biology k1 gene Apoptosis molecular markers fetal mismatch repair deficiency colorectal-cancer oncogene insulin Disabled-2 (DAB2) ulcerative-colitis BRCA1 deletion lung-cancer p53 gene squamous cancer esophageal cancer-erlotinib-response evaluation messenger-rna cancer patients subtypes Oncology gland human pancreatic-cancer mouse mammary models allele loss gastric-cancer epidemiology gene amplification poor-prognosis ROSE receptor-alpha coatings acetylation beta ovarian tumours Colon cancer estrogen gastroesophageal junction truncated int3 gene signature scarff-bloom-richardson prognostic factors cloning identification prostate-cancer AKT2 oncogene monoclonal-antibody myc-induced tumorigenesis lymphomas pseudomyxoma peritonei U50 amplification classifications circulating tumor-cells protein-kinase-b kinases suppressor Immunohistochemistry Genetics & Heredity detects frequent cell lung-cancer histological grades unit experimental mod spontaneous transformation chemotherapy ovarian GATA transcription factors induced apoptosis 1992 ang k-american journal of surgical pathology-v16-p259 therapy alpha gland involution dna-sequences conserving therapy immunohistochemistry bone metastases brca2 in-situ surface epithelial-cells chromatin allelic loss gefitinib growth-factor receptor survival margin status metastatic colorectal adenocarcinoma transcription repression localization multicentricity metastatic disease region breast epithelial-cells allelic imbalance multicenter
Last updated on Tuesday, April 02, 2019